Teglicar

Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) [1][2].

Product Specifications

CAS Number

[250694-07-6]

UNSPSC

12352211

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/teglicar.html

Purity

98.0

Solubility

DMSO : 19 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic; heat to 60°C) |H2O : 10 mg/mL (ultrasonic)

Smiles

O=C(N[C@H](CC([O-])=O)C[N+](C)(C)C)NCCCCCCCCCCCCCC

Molecular Formula

C22H45N3O3

Molecular Weight

399.61

References & Citations

[1]Roberto Conti, et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes. 2011 Feb;60 (2) :644-51.|[2]Carla Bertapelle, et al. The Reversible Carnitine Palmitoyltransferase 1 Inhibitor (Teglicar) Ameliorates the Neurodegenerative Phenotype in a Drosophila Huntington's Disease Model by Acting on the Expression of Carnitine-Related Genes. Molecules